Vol. 2 No. 13 (2006)

Published: 10 June 2009

It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006

Abstracts

State of Art on T-cell Lymphomas: The Epidemiology

R Liang

https://doi.org/10.4081/hmr.v2i13.474

227

PDF: 1291
- PDF
State of the Art on T-cell lymphomas: the Pathogenesis

ES Jaffe

https://doi.org/10.4081/hmr.v2i13.475

266

PDF: 678
- PDF
Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective

G Gisselbrecht

https://doi.org/10.4081/hmr.v2i13.476

220

PDF: 283
- PDF
Management of patients with peripheral T-cell lymphoma

JO Armitage

https://doi.org/10.4081/hmr.v2i13.477

232

PDF: 321
- PDF
Conventional treatment of peripheral T-cell lymphoma: the Asian perspective

K Tobinai

https://doi.org/10.4081/hmr.v2i13.478

243

PDF: 467
- PDF
T-cell lymphoma - standard treatment: The Mexican experience

A Avilès

https://doi.org/10.4081/hmr.v2i13.479

242

PDF: 382
- PDF
Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations

T Rüdiger

https://doi.org/10.4081/hmr.v2i13.480

253

PDF: 249
- PDF
Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfrα deregulation

SA Pileri, PP Piccaluga, C Agostinelli, S Zupo, A Carbone, F Facchetti, B Falini, M Ferrarini

https://doi.org/10.4081/hmr.v2i13.481

248

PDF: 267
- PDF
Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

RL Piekarz, R Frye, M Turner, J Turner, S Allen, MH Kirschbaum, J Zain, M Prince

https://doi.org/10.4081/hmr.v2i13.482

279

PDF: 378
- PDF
Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

SJ Proctor, J Wilkinson

https://doi.org/10.4081/hmr.v2i13.483

338

PDF: 1292
- PDF
Forodesine – Preclinical Studies

V Gandhi

https://doi.org/10.4081/hmr.v2i13.484

223

PDF: 719
- PDF
Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.485

321

PDF: 316
- PDF
Nelarabine – A New Age in the Management of Lymphoid Malignancies

MJ Keating

https://doi.org/10.4081/hmr.v2i13.486

289

PDF: 319
- PDF
New drugs for peripheral T-cell lymphomas

BD Cheson

https://doi.org/10.4081/hmr.v2i13.487

243

PDF: 368
- PDF
Cutaneous T-cell lymphomas: histology

M Santucci

https://doi.org/10.4081/hmr.v2i13.488

208

PDF: 220
- PDF
Molecular biology of cutaneous T-cell lymphomas

E Berti, S Gimelli, L Venegoni, V Merlo, R Riboni, O Zuffardi, M Paulli

https://doi.org/10.4081/hmr.v2i13.489

244

PDF: 268
- PDF
Alemtuzumab (Campath-1H)

C Querfeld, TM Kuzel, J Guitart, ST Rosen

https://doi.org/10.4081/hmr.v2i13.490

230

PDF: 280
- PDF
Optimizing denileukin diftitox (Ontak®) therapy

M Duvic

https://doi.org/10.4081/hmr.v2i13.491

255

PDF: 790
- PDF
Gemcitabine

M Tani, E Marchi, M Fina

https://doi.org/10.4081/hmr.v2i13.492

2123

PDF: 242
- PDF
Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects

U Wollina

https://doi.org/10.4081/hmr.v2i13.493

212

PDF: 488
- PDF
Interferons in cutaneous T-cell lymphomas

R Dummer, A Cozzio, M Urosevic

https://doi.org/10.4081/hmr.v2i13.494

226

PDF: 971
- PDF
Optimizing bexarotene therapy for cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i13.495

319

PDF: 801
- PDF
Bortezomib

PL Zinzani

https://doi.org/10.4081/hmr.v2i13.496

227

PDF: 250
- PDF
Animal models of T-cell lymphomas

Y-W Lin, PD Aplan

https://doi.org/10.4081/hmr.v2i13.497

246

PDF: 1255
- PDF
Rationale for the design of combination therapies that are active in T-cell lymphomas?

W Plunkett

https://doi.org/10.4081/hmr.v2i13.498

201

PDF: 212
- PDF
Peripheral T-cell lymphoma: prognostic factors

DD Weisenburger

https://doi.org/10.4081/hmr.v2i13.499

222

PDF: 435
- PDF
Prognostic factors in cutaneous T-cell lymphoma

R Willemze

https://doi.org/10.4081/hmr.v2i13.500

204

PDF: 954
- PDF
Chemotherapy for peripheral T-cell lymphoma

JM Vose

https://doi.org/10.4081/hmr.v2i13.501

211

PDF: 184
- PDF
Chemotherapy in cutaneous T-cell lymphoma

S Rupoli, MG Bernengo, R Alterini, M Cantonetti, PL Zinzani, N Pimpinelli

https://doi.org/10.4081/hmr.v2i13.502

246

PDF: 445
- PDF
Autotransplant in peripheral T-cell lymphomas

P Reimer

https://doi.org/10.4081/hmr.v2i13.503

203

PDF: 298
- PDF
Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome following reduced-intensity conditioning allogeneic stem cell transplantation

P Corradin, A Dodero, L Farina, M Casini, F Narni, F Patriarca, F Benedetti

https://doi.org/10.4081/hmr.v2i13.504

249

PDF: 242
- PDF
Auto and allotransplant in cutaneous T-cell lymphomas

F Onida

https://doi.org/10.4081/hmr.v2i13.505

216

PDF: 229
- PDF

Current Issue

Vol. 2 No. 13 (2006)

Abstracts

State of Art on T-cell Lymphomas: The Epidemiology

State of the Art on T-cell lymphomas: the Pathogenesis

Conventional treatment of peripheral T-cell lymphomas: view from GELA and European perspective

Management of patients with peripheral T-cell lymphoma

Conventional treatment of peripheral T-cell lymphoma: the Asian perspective

T-cell lymphoma - standard treatment: The Mexican experience

Nodal peripheral T-cell lymphomas correspond to distinct mature T-cell populations

Gene expression analysis of peripheral T-cell lymphoma not otherwise specified reveals two distinct subgroups and recurrent pdgfrα deregulation

Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

Current status of anti-CD30 monoclonal antibody therapy in anaplastic lymphoma and Hodgkin’s lymphoma

Forodesine – Preclinical Studies

Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma

Nelarabine – A New Age in the Management of Lymphoid Malignancies

New drugs for peripheral T-cell lymphomas

Cutaneous T-cell lymphomas: histology

Molecular biology of cutaneous T-cell lymphomas

Alemtuzumab (Campath-1H)

Optimizing denileukin diftitox (Ontak®) therapy

Gemcitabine

Liposomal chemotherapy in cutaneous T-cell lymphomas: current status and future prospects

Interferons in cutaneous T-cell lymphomas

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

Bortezomib

Animal models of T-cell lymphomas

Rationale for the design of combination therapies that are active in T-cell lymphomas?

Peripheral T-cell lymphoma: prognostic factors

Prognostic factors in cutaneous T-cell lymphoma

Chemotherapy for peripheral T-cell lymphoma

Chemotherapy in cutaneous T-cell lymphoma

Autotransplant in peripheral T-cell lymphomas

Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome following reduced-intensity conditioning allogeneic stem cell transplantation

Auto and allotransplant in cutaneous T-cell lymphomas

Categories